VERTEX PHARMACEUTICALS INC / MA (VRTX) Return on equity 2016–2025
VERTEX PHARMACEUTICALS INC / MA (VRTX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
21.2%FY2025 · since FY2016: -9.7% → 21.2%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 21.2% | +24.4 pp |
| FY2024 | -3.3% | -23.9 pp |
| FY2023 | 20.6% | -3.3 pp |
| FY2022 | 23.9% | +0.7 pp |
| FY2021 | 23.2% | -8.0 pp |
| FY2020 | 31.2% | +11.9 pp |
| FY2019 | 19.3% | -27.9 pp |
| FY2018 | 47.3% | +34.3 pp |
| FY2017 | 13.0% | +22.7 pp |
| FY2016 | -9.7% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More VRTX financial trends
VRTX RevenueVRTX Net incomeVRTX Net marginVRTX Gross profitVRTX Gross marginVRTX Operating incomeVRTX Operating marginVRTX Operating cash flowVRTX Free cash flowVRTX Capital expendituresVRTX Stock buybacksVRTX Dividends paidVRTX Total assetsVRTX Total liabilitiesVRTX Shareholders’ equityVRTX overview →